AR059829A1 - Sistemas estables de nanocapsulas para la administracion de moleculas activas - Google Patents
Sistemas estables de nanocapsulas para la administracion de moleculas activasInfo
- Publication number
- AR059829A1 AR059829A1 ARP070101016A ARP070101016A AR059829A1 AR 059829 A1 AR059829 A1 AR 059829A1 AR P070101016 A ARP070101016 A AR P070101016A AR P070101016 A ARP070101016 A AR P070101016A AR 059829 A1 AR059829 A1 AR 059829A1
- Authority
- AR
- Argentina
- Prior art keywords
- systems
- nanocapsules
- active molecules
- administration
- stable nanocapsules
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se dirige a sistemas nanocapsulares caracterizados por presentar una elevada estabilidad durante largos periodos de tiempo. Estos sistemas son utiles para la liberacion controlada de moléculas farmacologicamente o cosmetologicamente activas, especialmente de naturaleza fuertemente lipofílica. El sistema comprende nanocápsulas con un tamano medio inferior a 1 micrometro dispersas en un medio acuoso, donde las nanocápsulas tienen una estructura que comprende una fase lipofílica conteniendo un componente fosfolipídico y uno o más ácidos grasos de cadena C12-24 saturados y/o insaturados o derivados de los mismos; y una fase hidrofílica que comprende quitosano o un derivado del mismo y un compuesto polioxialquilenado. Composiciones farmacéuticas que comprenden dicho sistema y procedimiento de preparacion de dicho sistema.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06380048A EP1834635B1 (en) | 2006-03-13 | 2006-03-13 | Stable nanocapsule systems for the administration of active molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059829A1 true AR059829A1 (es) | 2008-04-30 |
Family
ID=36743270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070101016A AR059829A1 (es) | 2006-03-13 | 2007-03-13 | Sistemas estables de nanocapsulas para la administracion de moleculas activas |
Country Status (17)
Country | Link |
---|---|
US (1) | US20090074824A1 (es) |
EP (1) | EP1834635B1 (es) |
JP (1) | JP5222739B2 (es) |
KR (1) | KR20080102303A (es) |
CN (1) | CN101426479B (es) |
AR (1) | AR059829A1 (es) |
AT (1) | ATE515260T1 (es) |
AU (1) | AU2007224471B2 (es) |
BR (1) | BRPI0709594A2 (es) |
CA (1) | CA2646338A1 (es) |
DK (1) | DK1834635T3 (es) |
ES (1) | ES2369244T3 (es) |
IL (1) | IL194005A0 (es) |
PE (1) | PE20080141A1 (es) |
PL (1) | PL1834635T3 (es) |
PT (1) | PT1834635E (es) |
WO (1) | WO2007104732A2 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2653390C (en) * | 2006-06-02 | 2014-07-08 | Hawaii Chitopure, Inc. | Chitosan-derivative compounds and methods of controlling microbial populations |
US20080248508A1 (en) * | 2006-08-17 | 2008-10-09 | Shenda Baker | Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti-inflammatory cellular response to such materials |
KR20100062990A (ko) * | 2007-06-12 | 2010-06-10 | 크리스틴 알렌 | 국소적 약물전달을 위한 주사용 고분자-지질 배합물 |
EP2042166A1 (en) * | 2007-09-25 | 2009-04-01 | The Jordanian Pharmaceutical Manufacturing Co. | Nanocapsules for oral delivery of proteins |
SI2200588T1 (sl) * | 2007-09-25 | 2019-08-30 | Solubest Ltd. | Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo |
KR101199580B1 (ko) * | 2008-08-06 | 2013-11-27 | (주)에델프라우 | 국소 투여용 나노에멀젼 |
BRPI0805854A2 (pt) | 2008-10-10 | 2010-08-24 | Biolab Sanus Farmaceutica Ltda | sistema nanoparticulado, processo de preparaÇço do mesmo, uso do mesmo, composiÇço fotoproterora, processo de preparaÇço da mesma, mÉtodo de prevenÇço de doenÇas e distérbios da pele |
TWI328565B (en) * | 2008-12-19 | 2010-08-11 | Taiwan Textile Res Inst | Dispersions of conductive carbon materials and methods for preparing the same |
AU2010223329B2 (en) | 2009-03-12 | 2016-07-21 | Keybioscience Ag | Treatment of diabetes and metabolic syndrome |
ES2347119B2 (es) * | 2009-04-22 | 2011-04-28 | Universidad De Santiago De Compostela | Nanocapsulas de poliarginina. |
EP2266546A1 (en) * | 2009-06-08 | 2010-12-29 | Advancell Advanced in Vitro Cell Technologies,S.A. | Process for the preparation of colloidal systems for the delivery of active compounds |
EP2364600A1 (en) * | 2010-02-18 | 2011-09-14 | Nestec S.A. | Liquid-filled chitosan-anionic liposoluble capsule dispsersions |
BRPI1002601E2 (pt) * | 2010-06-01 | 2020-06-30 | Embrapa Pesquisa Agropecuaria | composição nanoestruturada de uso veterinário para administração de fármacos |
JP6189749B2 (ja) * | 2010-06-23 | 2017-08-30 | ブライトサイド イノベーションズ,インコーポレイティド | レシチン担体小胞とその作製方法 |
US20140005269A1 (en) * | 2010-11-26 | 2014-01-02 | University Of The Witwatersrand, Johannesburg | Polymeric matrix of polymer-lipid nanoparticles as a pharmaceutical dosage form |
US9801829B2 (en) * | 2011-04-29 | 2017-10-31 | University Of Florida Research Foundation, Inc. | Methods and systems of making nanostructures |
DE102011076149A1 (de) * | 2011-05-19 | 2012-11-22 | Rovi Cosmetics International Gmbh | Ladungsgeber für ein vesikuläres Trägersystem eines UV-Schutzmittels für die Haut oder die Haare |
ES2366255B2 (es) * | 2011-06-27 | 2012-08-08 | Universidade De Santiago De Compostela | Nanocomposiciones sacarídicas para la liberación de vacunas. |
AU2012332265B2 (en) | 2011-11-02 | 2016-11-10 | Keybioscience Ag | Peptide analogs for treating diseases and disorders |
EP3357540A1 (en) | 2011-11-02 | 2018-08-08 | KeyBioscience AG | Combination of calcitonin mimetic and insulin sensitizer |
AU2012339701B8 (en) * | 2011-11-15 | 2017-11-16 | Allergan, Inc. | Autoclavable suspensions of cyclosporin A Form 2 |
US8968790B2 (en) * | 2011-12-09 | 2015-03-03 | Shaker A. Mousa | Nanoformulation of vitamin D derivatives and/or vitamin D metabolites |
EP2625966A1 (en) | 2012-02-13 | 2013-08-14 | Bionanoplus, S.L. | Nanoparticles comprising a vegetable hydrophobic protein and a water miscible non-volatile organic solvent and uses thereof |
US10010630B2 (en) * | 2012-12-21 | 2018-07-03 | Bracco Suisse S.A. | Gas-filled microvesicles |
EP3057604B1 (en) | 2013-10-14 | 2021-06-09 | Nanosphere Health Sciences Inc. | Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers |
PL3068796T3 (pl) | 2013-11-14 | 2018-07-31 | Keybioscience Ag | Mimetyki kalcytoniny do leczenia chorób i zaburzeń |
CN104117066B (zh) * | 2014-07-16 | 2016-03-02 | 陈凌 | 外敷用抗甲状腺软膏的制备方法 |
WO2016100228A2 (en) * | 2014-12-15 | 2016-06-23 | Nanosphere Health Sciences, Llc | Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of nsaids |
GB201500263D0 (en) | 2015-01-08 | 2015-02-25 | Keybioscience Ag | Calcitonin analogues for treating diseases and disorders |
AU2015385825A1 (en) | 2015-03-10 | 2017-10-05 | Nanosphere Health Sciences, Llc | Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms |
PL229276B1 (pl) * | 2015-07-17 | 2018-06-29 | Univ Jagiellonski | Nanokapsuła do przenoszenia związku lipofilowego i sposób jej wytwarzania |
CN116999410A (zh) * | 2015-08-11 | 2023-11-07 | Eyesiu医疗股份有限公司 | 具有生物活性亲脂性化合物的聚乙二醇化脂质纳米粒 |
US10765639B2 (en) * | 2016-03-25 | 2020-09-08 | Adisseo France S.A.S. | Nanocapsules, methods of manufacture and uses thereof |
GB201704429D0 (en) | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
GB201707955D0 (en) | 2017-05-18 | 2017-07-05 | Keybioscience Ag | Dual amylin and calcitonin receptor agonists for treating diseases and disorders |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
GB201813677D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
GB201813678D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
CN109316602A (zh) * | 2018-11-13 | 2019-02-12 | 西安力邦医药科技有限责任公司 | 一种长效镇痛并促进伤口愈合的复方缓释递药系统的组方与应用 |
EP4272731A3 (en) | 2018-12-11 | 2024-02-14 | Disruption Labs Inc. | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
KR102384808B1 (ko) * | 2018-12-20 | 2022-04-08 | 주식회사 스킨메드 | 키토산으로 코팅된 나노 캡슐 및 이의 용도 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL101241A (en) * | 1992-03-16 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier |
EP0570829B1 (de) * | 1992-05-18 | 2001-04-25 | CicloMulsion AG | Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung |
US20030224022A1 (en) * | 1993-01-19 | 2003-12-04 | Amos Nussinovitch | Hydrocolloid cellular solid matrices |
US5744155A (en) * | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
ES2093562B1 (es) * | 1995-05-26 | 1997-07-01 | Univ Santiago Compostela | Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. |
US6649192B2 (en) * | 1996-07-29 | 2003-11-18 | Universidade De Santiago De Compostela | Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms |
JP3441665B2 (ja) * | 1999-02-04 | 2003-09-02 | 株式会社資生堂 | (2−置換オキシフェニル)アルカンアミド誘導体及び養毛剤、皮膚外用剤 |
EP1190702A1 (en) * | 2000-09-22 | 2002-03-27 | Ciba SC Holding AG | Chitosan emulsion formulation |
EP1243323B1 (de) * | 2001-03-22 | 2005-01-05 | Cognis Iberia, S.L. | Nanokapseln |
CN100335036C (zh) * | 2001-11-01 | 2007-09-05 | 耶路撒冷希伯来语大学依苏姆研究开发公司 | 用于干眼症治疗的方法和组合物 |
-
2006
- 2006-03-13 ES ES06380048T patent/ES2369244T3/es active Active
- 2006-03-13 AT AT06380048T patent/ATE515260T1/de active
- 2006-03-13 EP EP06380048A patent/EP1834635B1/en active Active
- 2006-03-13 PT PT06380048T patent/PT1834635E/pt unknown
- 2006-03-13 PL PL06380048T patent/PL1834635T3/pl unknown
- 2006-03-13 DK DK06380048.6T patent/DK1834635T3/da active
-
2007
- 2007-03-09 PE PE2007000261A patent/PE20080141A1/es not_active Application Discontinuation
- 2007-03-12 US US12/282,366 patent/US20090074824A1/en not_active Abandoned
- 2007-03-12 KR KR1020087024897A patent/KR20080102303A/ko active IP Right Grant
- 2007-03-12 BR BRPI0709594-5A patent/BRPI0709594A2/pt not_active IP Right Cessation
- 2007-03-12 AU AU2007224471A patent/AU2007224471B2/en not_active Ceased
- 2007-03-12 CA CA002646338A patent/CA2646338A1/en not_active Abandoned
- 2007-03-12 CN CN2007800139239A patent/CN101426479B/zh not_active Expired - Fee Related
- 2007-03-12 WO PCT/EP2007/052276 patent/WO2007104732A2/en active Application Filing
- 2007-03-12 JP JP2008558798A patent/JP5222739B2/ja not_active Expired - Fee Related
- 2007-03-13 AR ARP070101016A patent/AR059829A1/es unknown
-
2008
- 2008-09-09 IL IL194005A patent/IL194005A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2369244T3 (es) | 2011-11-28 |
KR20080102303A (ko) | 2008-11-24 |
IL194005A0 (en) | 2011-08-01 |
CA2646338A1 (en) | 2007-09-20 |
WO2007104732A3 (en) | 2007-11-08 |
EP1834635B1 (en) | 2011-07-06 |
BRPI0709594A2 (pt) | 2011-07-19 |
PL1834635T3 (pl) | 2012-01-31 |
DK1834635T3 (da) | 2011-10-24 |
WO2007104732A2 (en) | 2007-09-20 |
JP2009530241A (ja) | 2009-08-27 |
AU2007224471B2 (en) | 2013-05-02 |
PT1834635E (pt) | 2011-10-13 |
EP1834635A1 (en) | 2007-09-19 |
JP5222739B2 (ja) | 2013-06-26 |
AU2007224471A1 (en) | 2007-09-20 |
US20090074824A1 (en) | 2009-03-19 |
CN101426479B (zh) | 2012-10-10 |
CN101426479A (zh) | 2009-05-06 |
PE20080141A1 (es) | 2008-03-04 |
ATE515260T1 (de) | 2011-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059829A1 (es) | Sistemas estables de nanocapsulas para la administracion de moleculas activas | |
ES2531646T3 (es) | Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno | |
PE20191714A1 (es) | Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso | |
CO6220926A2 (es) | Formulacion farmaceutica topica para la aplicacion de un farmaco antiinflamatorio no esferoidal (nsaid) | |
BR112016018673A2 (pt) | Composições de sistemas de distribuição de nanoemulsão | |
EA201490921A1 (ru) | Устойчивые составы с контролируемым высвобождением | |
AR081535A1 (es) | Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso | |
PE20070377A1 (es) | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol | |
BRPI0615292A8 (pt) | composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada | |
CL2011000244A1 (es) | Formulacion farmaceutica intra-arterial que comprende particulas esfericas que contienen un factor de crecimiento y un excipiente biodegradable, en donde el diametro medio de dichas particulas es de 15-20 micrometros, con una desviacion estandar de (+/-) 1 micrometro en al menos 99% de las particulas; y su uso en el tratamiento de infarto al miocardio, trastorno cardiaco isquemico, entre otros. | |
TR200801336T1 (tr) | Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler. | |
CL2009002073A1 (es) | Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares. | |
CO6231001A2 (es) | Estabilizacion de vitamina b12 | |
AR053737A1 (es) | Formulacion pediatrica de topiramato | |
EA201270050A1 (ru) | Нанодисперсия лекарственного средства и способ ее получения | |
AR056808A1 (es) | Formulacion de aceite en agua de avermectinas | |
MX351430B (es) | Pre-concentrado lipídico de liberación sostenida de una sustancia farmacológicamente activa y una composición farmacéutica que comprende el mismo. | |
PE20071244A1 (es) | Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas) | |
AR089004A1 (es) | Composiciones farmaceuticas inyectables, metodo, uso | |
AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
ES2721148T3 (es) | Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso | |
BRPI0712142A8 (pt) | Formulações farmacêuticas para a liberação prolongada de princípio(s) ativo(s), bem como suas aplicações, especialmente aplicações terapêuticas | |
NZ610465A (en) | Clevidipine emulsion formulations containing antimicrobial agents | |
AR077338A1 (es) | Formulacion farmaceutica. procedimiento de preparacion. disolucion para perfusion. | |
CL2011001225A1 (es) | Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |